Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2015-08-25 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
CHANGE OF COMPANY WEBSITE
Regulatory Filings Classification · 95% confidence The document is a short announcement from the board of directors about a change in the company's website. It does not contain any financial data, report content, or detailed management information. It is not a report itself but a brief regulatory announcement. The document length is only 1221 characters, which is very short and fits the pattern of a regulatory announcement rather than a full report or detailed filing. There is no indication of financial results, voting results, or management changes beyond the website update. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2015-08-25 English
2015 INTERIM RESULTS ANNOUNCEMENT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2015 Interim Results Announcement' and contains detailed unaudited consolidated financial statements for the six months ended 30 June 2015, including profit and loss, financial position, segment information, notes on accounting policies, and tax expenses. It explicitly states preparation under HKAS 34 Interim Financial Reporting and includes substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, indicating it is the report itself, not just an announcement of its publication. Therefore, the correct classification is IR with high confidence. H1 2015
2015-08-25 English
Date of Board Meeting
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a Board meeting to approve unaudited results for the six months ended 30 June 2015. It does not contain any financial data or detailed report content but merely announces the upcoming board meeting and the agenda to approve interim results. The length is only 1294 characters, which is very short and fits the pattern of an announcement rather than a full interim or quarterly report. According to the rules, such short announcements about board meeting dates and report approvals are classified as Regulatory Filings (RNS) because they do not contain substantive financial data or the report itself.
2015-08-13 English
VOLUNTARY ANNOUNCEMENT - THE GROUP'S COUGH SUPPRESSANT PRODUCT "BENZONATATE SOFT CAPSULE" WAS GRANTED DRUG REGISTRATION APPROVAL BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of their product 'Benzonatate Soft Capsule' by the U.S. FDA. It is a short announcement (2635 characters) focused on a regulatory milestone related to product approval, not a financial report or detailed corporate filing. There is no financial data, no mention of annual or quarterly results, no voting results, no management changes, or other report types. The document is an announcement of a regulatory event related to product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2015-08-05 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2015
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/07/2015, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during a specific month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting monthly share capital movements, typical of a capital/financing update or a regulatory compliance report. Given the detailed share capital movement data and the nature of the filing, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a simple notice, but a substantive monthly capital movement report.
2015-08-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2015
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/06/2015, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related activities for CSPC Pharmaceutical Group Limited. The content focuses on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements for a specific month, typical of a capital/financing update or a regulatory compliance report. Given the detailed share capital movements and the nature of the document, it fits best under Capital/Financing Update (CAP). The document length is substantial and contains actual data, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2015-07-06 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.